Accurate Integration of PiggyBac Transposon into Defined Genome Locus by using Engineered PBase fused to Cas9
Xu Naiqing, Hu Xiaohan, Fang Yuan, Liu Jingxian, Sun Kailiang, Xu Tian.
In GeCell Therapeutics, we leverage the power of non-viral genetic engineering and gene delivery technologies to develop novel gene and cell therapies for genetic diseases and cancers.
The PiggyBac transposon system is a safe and highly efficient genetic engineering approach for multiple types of cells with remarkable cost benefits. The large cargo capacity allows integration of multiple functional or regulatory elements for various purposes in a single-step engineering.
We are applying the PiggyBac platform to both ex vivo and in vivo gene therapy developments. At the same time,
we are also modifying the PiggyBac transposase to enable site specific gene transfer.
We have developed proprietary gene delivery technologies based on cationic polymers with validated nucleic acid delivery efficiency. The polymer platform also offers incredible versatility through structural modification for efficient encapsulation and delivery of various types of cargos (DNA, mRNA, siRNA, RNP, etc) in multiple types of cells or tissues.


GeCell Therapeutics, LLC*, (“GeCell”), has received the notification from the National Medical Products Administration of the People’s Republic of China regarding approval of the clinical trial of GC101 (the “Product”) for the graft treatment of incurable body wounds in patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB).

Board of directors;Adjunct Professor of Yale University; Vice President of West Lake University
Tian Xu is a Founder and Chair of Drug Farm. He is Chair Professor of Genetics and Vice President of Westlake University and Adjunct Professor of Genetics at Yale University. He was an endowed Professor at Yale Medical School and an Investigator of the Howard Hughes Medical Institute for more than two decades before joining Westlake. He served as President of the Chinese Biological Investigators Society and Chair of the Scientific Advisory Board for the Rothberg Institute for Childhood Diseases. The major thrust of Xu’s research effort lies in developing and utilizing novel genetic approaches to understand development and disease. The systematic functional genetics methods that he developed for Drosophila, mice and human cells have been used by the research community throughout the world. In recent years, Dr. Xu explores artificial intelligence and intelligence in research and translation.

Bachelor of Nanjing University, Ph.D. of Cornell University, Postdoctoral of Rockefeller University
Associate Professor of the University of Chicago, the focus of research is the biology of skin stem cells and skin diseases.

Bachelor of Sichuan University, Ph.D. of Iowa State University, Poor Postdoctoral University of California, Berkeley
Yi Jin has more than 20 years of academic research and enterprise research and development experience, including the University of California, Berkeley, Bayer, Kingsley and other internationally renowned institutes, large pharmaceutical companies and CROs. She focuses on tumor immunity, autoimmune, single-gene genetic diseases, etc., and has rich early research and preclinical development experience, including promoting technology platform construction. In terms of academic research, there are dozens of academic papers in academic research in journals such as Cell, Molecular Cell, Development Cell, J. Cell Biol., J. Cell. BioChem. She has rich team management capabilities, including multi-disciplinary and cross-professional team management, especially early R & D, transformation of medicine and preclinical pharmacy, such as CMC, QA/QC, etc.

Bachelor of Changchun University of Traditional Chinese Medicine, Ph.D. in Hengbin City University in Japan
Weili Cong has more than 10 years of experience in the research and development and process development of cell therapy products, including IPS cells, etc. She was an associate researcher at the Shanghai Biochemical Institute

Bachelor of Shanghai Jiaotong University, Ph.D. in Shanghai Jiaotong University
He has experience and quality management experience in Shanghai Rice Blood Products for nearly 10 years; he also has rich team management and coordination capabilities.

GeCell therapeutics has cGMP compliant facility for process development and manufacture of NK cells derived from PBMC and iPSC.
Our aim is to develop off-the-shelf immunotherapy product against blood and solid tumors. The production of NK cells involves sophisticated steps, including gene editing, gene delivery by PiggyBac transposase and cell differentiation and maturation.
By the end of 2023, we will enter a new facility, a 4000-square-meter complex, located at Shanghai Zhangjiang district. The facility will support our iPSC-derived NK R&D and, more importantly, expand our manufacture capacity.
Accurate Integration of PiggyBac Transposon into Defined Genome Locus by using Engineered PBase fused to Cas9
Xu Naiqing, Hu Xiaohan, Fang Yuan, Liu Jingxian, Sun Kailiang, Xu Tian.
Treatment of Recessive Dystrophic Epidermolysis Bullosa by Transplantation of COL7A1 Transgenic Tissue-engineered Skin Grafts
Xiaogang Deng, Weili Cong, Zhiming Chen, Zheng Zhang, Xian Liu, Wenjing Bai, Yijun Li, Xi Wang, Yingcun Wang, Qianqian Chen, Liwen Zhang, Xihui Gu, Yi Zhang, Kailiang Sun, Xiaoyang Wu, Yong Yang, Tian Xu.
We seek highly motivated talents to join our team to make tangible impact to the lives with incurable diseases. If you are interested in exploring opportunities with GeCell, please send your CV to joinus@gecelltx.com.
Vision: To become an innovative gene and cell therapy company
Mission: Writing healthy lives
Quality Assurance: Strive for quality excellence in developing innovative gene and cell therapies to improve and cure human diseases
Patient-oriented and innovation-driven research and development
Keep improving for the best

Address:
Building #1
1111 North Zhongshan 1st Road
Shanghai 200437
China
Business:
E-mail: office@gecelltx.com
Phone: 021-55670608